Ambalal Sarabhai Enterprises Ltd

AI
Ambalal Sarabhai Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Ambalal Sarabhai Enterprises Ltd

₹ 46.3 -2.71%
19 Aug - close price
ase.life BSE: 500009 NSE: AMBALALSA
About

Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]

Key Points

Business Overview:[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad

Website BSE NSE
  • Market Cap ₹ 354 Cr.
  • Current Price ₹ 46.3
  • High / Low ₹ 50.0 / 23.1
  • Stock P/E 85.6
  • Book Value ₹ 7.76
  • Dividend Yield 0.00 %
  • ROCE 16.4 %
  • ROE 20.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 5.97 times its book value
  • Promoter holding is low: 31.4%
  • Tax rate seems low
  • Company has a low return on equity of 12.1% over last 3 years.
  • Earnings include an other income of Rs.9.11 Cr.
  • Working capital days have increased from 267 days to 1,379 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
1.70 0.80 0.33 0.99 1.14 0.00 1.17 1.73 1.64 0.79 0.00 1.52 0.54
4.84 2.13 1.96 1.64 2.41 1.80 3.74 3.43 2.83 2.43 0.94 2.88 1.76
Operating Profit -3.14 -1.33 -1.63 -0.65 -1.27 -1.80 -2.57 -1.70 -1.19 -1.64 -0.94 -1.36 -1.22
OPM % -184.71% -166.25% -493.94% -65.66% -111.40% -219.66% -98.27% -72.56% -207.59% -89.47% -225.93%
1.18 1.96 1.33 3.41 1.88 6.37 10.81 -3.21 8.17 1.36 2.89 3.16 1.70
Interest 0.03 0.04 0.06 0.07 0.09 0.09 0.10 0.05 0.07 0.08 0.09 0.17 0.17
Depreciation 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Profit before tax -2.02 0.56 -0.39 2.66 0.49 4.45 8.12 -4.98 6.89 -0.38 1.84 1.61 0.29
Tax % 0.00% 0.00% 69.23% -76.32% 6.12% 3.15% -3.82% -0.40% 0.00% 0.00% -0.54% -64.60% 89.66%
-2.02 0.56 -0.65 4.70 0.46 4.31 8.43 -4.96 6.88 -0.38 1.84 2.65 0.03
EPS in Rs -0.26 0.07 -0.08 0.61 0.06 0.56 1.10 -0.65 0.90 -0.05 0.24 0.35 0.00
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
15.25 6.98 1.51 0.92 0.00 0.00 0.00 0.13 3.71 3.81 4.04 3.94 2.85
27.30 28.62 14.47 21.76 8.86 7.86 11.69 5.71 8.87 8.61 11.37 9.06 8.01
Operating Profit -12.05 -21.64 -12.96 -20.84 -8.86 -7.86 -11.69 -5.58 -5.16 -4.80 -7.33 -5.12 -5.16
OPM % -79.02% -310.03% -858.28% -2,265.22% -4,292.31% -139.08% -125.98% -181.44% -129.95% -181.05%
14.17 95.94 -0.63 24.49 6.46 24.61 3.16 9.47 9.75 7.89 15.85 15.57 9.11
Interest 7.91 1.99 2.62 1.05 0.62 0.46 0.56 0.25 0.11 2.16 0.34 0.41 0.51
Depreciation 3.36 14.62 2.45 0.42 0.40 0.39 0.38 0.19 0.15 0.12 0.10 0.09 0.08
Profit before tax -9.15 57.69 -18.66 2.18 -3.42 15.90 -9.47 3.45 4.33 0.81 8.08 9.95 3.36
Tax % 0.00% 20.80% 10.18% 166.06% 13.45% 2.20% -0.84% 14.49% 5.31% -217.28% -1.98% -10.45%
-9.15 45.68 -20.57 -1.44 -3.88 15.55 -9.39 2.96 4.11 2.58 8.24 10.99 4.14
EPS in Rs -1.19 5.96 -2.68 -0.19 -0.51 2.03 -1.23 0.39 0.54 0.34 1.08 1.43 0.54
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: -6%
5 Years: %
3 Years: 2%
TTM: -37%
Compounded Profit Growth
10 Years: 9%
5 Years: 44%
3 Years: 32%
TTM: -71%
Stock Price CAGR
10 Years: 22%
5 Years: 9%
3 Years: 20%
1 Year: 37%
Return on Equity
10 Years: 2%
5 Years: 12%
3 Years: 12%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 76.63 76.63 76.63 76.63 76.63 76.63 76.63 76.63 76.63 76.63 76.63 76.63
Reserves -73.49 -27.80 -46.41 -47.98 -51.85 -36.39 -45.85 -42.93 -38.79 -36.34 -28.14 -17.15
30.10 29.54 22.13 11.07 11.07 11.00 11.14 9.77 11.49 10.03 7.66 11.00
103.24 65.13 63.81 91.28 102.78 73.35 58.14 39.53 30.42 30.96 26.77 15.31
Total Liabilities 136.48 143.50 116.16 131.00 138.63 124.59 100.06 83.00 79.75 81.28 82.92 85.79
42.66 20.60 16.43 14.98 14.65 14.48 13.97 13.00 12.86 12.84 12.22 12.13
CWIP 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Investments 56.29 82.91 76.19 55.88 55.97 56.43 26.58 25.54 25.54 25.39 25.34 25.34
37.43 39.99 23.54 60.14 68.01 53.68 59.51 44.46 41.35 43.05 45.36 48.32
Total Assets 136.48 143.50 116.16 131.00 138.63 124.59 100.06 83.00 79.75 81.28 82.92 85.79

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-12.05 -69.37 -3.67 -12.66 -3.27 -4.53 -10.42 -7.79 1.52 -3.82 -4.08 -0.26
12.70 75.22 8.64 26.14 2.37 4.92 15.76 20.77 0.61 3.48 6.35 -3.02
-0.75 -2.56 -8.14 -12.15 -0.44 -0.42 -0.32 -16.46 -3.76 0.30 -2.31 3.40
Net Cash Flow -0.10 3.30 -3.17 1.33 -1.33 -0.03 5.02 -3.47 -1.63 -0.04 -0.04 0.11
Free Cash Flow -0.49 31.11 -3.04 1.72 -3.33 -4.50 0.66 11.47 1.58 -3.91 1.11 -0.27
CFO/OP 71% 304% 27% -24% -11% 51% 85% 128% -45% 65% 47% 61%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 37.34 1.57 0.00 0.00 421.15 29.51 37.36 37.04 38.91
Inventory Days 76.36 22.52 47.93 56.64 0.00 2.01 0.00 0.00 6.62
Days Payable 320.68 729.22 3,974.44 13,253.28 1,611.83 712.03
Cash Conversion Cycle -206.97 -705.13 -3,926.52 -13,196.64 421.15 -1,580.31 37.36 37.04 -666.51
Working Capital Days -2,355.15 -3,035.57 -16,105.93 -23,784.51 -30,660.00 -1,037.94 -686.89 109.32 1,379.40
ROCE % -34.09% -59.62% -12.82% -21.98% -7.41% 36.90% -4.27% 9.93% 11.12% 5.96% 6.01% 16.36%

Insights

In beta
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Domestic Sales Share
%

Log in to view insights

Please log in to see hidden values.

Login
Pharmaceuticals Segment Revenue Share
%
Number of Subsidiaries
subsidiaries
Major Customer Revenue Contribution
%
Number of Registered Products (Asence Group)
products
Number of IVD Approved Molecular Tests (CoSara Diagnostics)
tests

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
30.78% 30.78% 30.78% 30.78% 31.35% 31.35% 31.35% 31.35% 31.35% 31.36% 31.36% 31.36%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.38% 0.38% 0.34% 0.34% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.10% 0.10% 0.00% 0.00% 0.00% 0.00% 0.00%
69.23% 69.21% 69.23% 69.22% 68.65% 68.54% 68.18% 68.26% 68.32% 68.29% 68.64% 68.64%
No. of Shareholders 1,75,2221,71,9441,70,0791,69,2281,72,3381,71,2211,70,9121,69,6301,70,0151,68,3961,67,5991,67,066

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports